Specialty drugs represent the fastest-growing segment of drug spend in the US. In fact, recent estimates show that by 2014 specialty drug spend will comprise 40% of US total drug spend. Additionally, over 50% of specialty drug spend is driven by drugs provided as part of the medical benefit, which are not covered by the programs in place to manage pharmacy benefit drugs.
AIM's Specialty Drugs program provides review for over 100 specialty drugs offering providers an automated drug review process through our provider friendly web portal.
AIM's program covers over 10 million members in 13 states.